MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.
Morphotek Inc is developing MORAb-003, a humanized monoclonal antibody directed against folate receptor alpha, for the potential treatment of ovarian cancer. Phase II clinical trialsof MORAb-003, either alone or in combination with platinum/taxane chemotherapy, are underway in ovarian cancer patients experiencing their first disease recurrence.
Kalli
Kimberly R
KR
Mayo Clinic College of Medicine, Women's Cancer Program, 200 First Street SW, Rochester, MN 55905, USA. kalli.kimberly@mayo.edu
D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D016466:CHO Cells; D002352:Carrier Proteins / Q000037:antagonists & inhibitors*; D045744:Cell Line, Tumor; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006224:Cricetinae; D003412:Cricetulus; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical; D004847:Epithelial Cells / Q000187:drug effects*; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D005334:Fever / Q000139:chemically induced; D058973:Folate Receptors, GPI-Anchored; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D020128:Inhibitory Concentration 50; D051379:Mice; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000628:therapy*; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors*; D023041:Xenograft Model Antitumor Assays
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D002352:Carrier Proteins; D058973:Folate Receptors, GPI-Anchored; D011956:Receptors, Cell Surface; C527484:farletuzumab